Established and novel insights to guide cancer assessment in patients with idiopathic inflammatory myopathies
Authors' conclusion
Recent IMACS guidelines perform well in the interception of cancer, yet adjunctive history and laboratory features should be considered. Patients with anti-TIF1-γ antibodies are at risk of cancer-associated myositis, but concurrent autoantibodies negatively correlate with malignancy and warrant characterization.
Study context
- Population
- Patients with IIM, serum autoantibodies tested by HEp-2, immunoassays, RNA- and protein-immunoprecipitationmedian follow-up 6 years (IQR 3–11)
- Participants
- 95 patients
- Outcome
- Prevalence of cancer; association to disease features; performance of IMACS guidelines
Main finding
As reported in the abstract
Cancer prevalence in IIM · median follow-up 6 years (IQR 3-11)
Cancer diagnosis
22 of 95
23 %
Cancer-associated myositis (malignancy within 3 years before or after myositis onset)
14 %
Observational data: associations, not effects.
Further findings
Features associated with overall cancer and cancer-associated myositis
- More respiratory comorbidities, anemia, hypergammaglobulinemia and DM phenotype
Anti-TIF1-γ antibody positivity
- Predicted cancer-associated myositis but not overall cancer rate
- Malignancy particularly with isolated anti-TIF1-γ; lower prevalence with additional specificities by immunoprecipitation
Original publication
Established and novel insights to guide cancer assessment in patients with idiopathic inflammatory myopathies. Semin Arthritis Rheum. Published 22 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →